Arcas News
March 18th, 2011
A number of current events are going to have a significant impact on the treatment of metastatic breast cancer in Europe: the EMA has recently reduced the marketing approval for bevacizumab and new positive data from the EMBRACE trial (eribulin in the recurrent setting) were made available.
MDoutlook launched a Quick Poll™ among its 12,000+ European medical oncology members to determine how these events are and will be affecting clinical practice. Responses from 13 countries (>60% of responses were from the 5-EU) show the following:
• Initial uptake in usage of eribulin will be stronger in later lines of treatment, although a majority of oncologists will begin using eribulin in the 2nd line for some of their metastatic breast cancer patients (see figure below)
• It is widely believed that eribulin will soon prove to be effective as an initial treatment for metastatic breast cancer with less acceptance as a neoadjuvant or adjuvant agent
• Significant reductions in the use of bevacizumab + docetaxel in metastatic breast cancer have recently been made by oncologists; further reductions in the use of this combination will occur due to the EMA’s decision
• The use of bevacizumab + paclitaxel, which was unaffected by the recent EMA decision, has had and will have only some minor reductions in usage for metastatic breast cancer. The use of bevacizumab in other tumor types are also relatively unaffected
To download a free copy of this MDoutlook report (in .pdf format), click here Changing European Paradigms for the Treatment of Metastatic Breast Cancer.
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader-composed Strategy Councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 51,000+ cancer treaters and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information about MDoutlook or to receive PowerPoint slides of this report, please email info@MDoutlook.com or call +1.404.496.4136.
March 18th, 2011
February 15th, 2011
Last Thursday, two articles in the New England Journal of Medicine described exciting results with sunitinib (Sutent®) and everolimus (Afinitor®) from phase III clinical trials in pancreatic neuroendocrine tumors (PNET). To gauge the immediate impact these reports could have with the global oncology community, MDoutlook launched a global Quick Poll™ of its medical oncology members. Based on the initial results collected over the weekend:
• While 40-50% of oncologists are already using sunitinib or everolimus for the treatment of some of their patients with PNET, over 80% plan on using them in 2011
• The amount of patients with PNET who will receive sunitinib or everolimus for treatment in 2011 is predicted to expand by 2.5-3.0 fold over current levels (see figure below)
• Three quarters of oncologists expect their PNET patients will stay on extended therapy with these agents regardless of the potential for serious side effects
• Usage of these agents in PNET will have little to no effect on their use in metastatic renal cell carcinoma (where both currently have FDA-approval).
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader composed-strategy councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 50,000 oncologists and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information about MDoutlook or to receive a final copy of this report when it is available next week, please email info@mdoutlook.com or call +1.404.496.4136.
February 15th, 2011
Recently, MDoutlook was featured in two articles that will help our clients and contacts with your marketing planning and tactics in 2011. We gladly share these with you.
• MDoutlook oncology insight and market adoption trends are featured in this month’s Oncology Business Review (OBR). More than 500 oncologists responded to exclusive Quick Polls fielded immediately after the December American Society of Hematology meeting (ASH) and San Antonio Breast Cancer Symposium (SABCS). We are offering you complimentary access to the full report here.
• Pharmaceutical Executive has interviewed MDoutlook to provide perspectives on 2011 trends in Pharma, with a focus on oncology. You can read the article here.
MDoutlook is a unique web-based, disease intelligence platform that provides a comprehensive view of clinical decision patterns and treatment choices. Guided by ThoughtLeader composed-strategy councils, MDoutlook offers:
• Treatment Decision Reports and Analysis
• Real-time Chart Pulls with Treatment Decision Rationale
• Current profiles of 50,000 oncologists and their institutions
• ThoughtLeader Influence Mapping and Referral Mapping, as revealed directly by clinicians
For more information please email info@MDoutlook.com or call +1.404.496.4136.
January 24th, 2011
FOR IMMEDIATE RELEASE
CONTACT:
Jan A. Heybroek – President, The Arcas Group, LLC
jheybroek[at]thearcasgroup.com
+1.404.496.4136
MDOUTLOOK® Quick Polls from the Major Oncology/Hematology Meetings ASH and SABCS: First Report from Cancer Treaters on Clinical Impact of New Cancer Developments
Atlanta, GA, United States – December 21, 2010
MDOUTLOOK®, the oncology intelligence initiative powered by The Arcas Group, today announced results from its series of immediate Quick Poll research launched following major oncology and hematology market moving events. These Quick Polls examined the potential clinical impacts from the American Society of Hematology (ASH) annual meeting in Orlando and the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). This effort expands on previous Quick Poll research carried out after the American Society of Clinical Oncology (ASCO) annual meetings in 2009 and 2010.
Within one week, 506 cancer treaters from over 30 countries responded to the Quick Poll research following the ASH and SABCS meetings, making this the first market feedback available post-ASH and post-SABCS. Some of the highlights from this research include:
• Decisions concerning the use of drugs are primarily made independently of any indications / approvals in different malignancies, even if it is in a related tumor type.
• Maintenance therapy with lenalidomide is seen as a highly important advance in the management of multiple myeloma. It is expected that half of all patients with multiple myeloma will receive this therapeutic approach in 2011.
• There appears to be a new standard of care for mantle cell lymphomas: alternating cycles of CHOP and DHAP (both with rituximab), followed by high dose ARA-C and autologous stem cell transplantation.
• Oncologists / Hematologists are not differentiating primary from secondary AML in their outlook for new therapeutics.
• New data showing a lack of association between CYP2D6 phenotype and tamoxifen responsiveness will cut in half the amount of CYP2D6 genotyping being performed in postmenopausal women with HR+ breast cancer from 11 to 5%.
• Dual targeting the HER2 receptor is a very important clinical advance for HER2+ breast cancer. The use of this strategy in appropriate breast cancer subtypes with currently available therapeutics is expected to double in 2011.
Members of the MDOUTLOOK Strategy Council reflected that these results “show the quick and strong uptake of new developments presented into physician decision-making on a global scale” and that “it will be of value to follow-up on a regular basis to track these changes.”
Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to quickly and in a targeted manner capture the views of validated cancer physicians around the world, and turn this into actionable intelligence.”
These Quick Polls are the seventh in a series of Quick Polls following major oncology conferences. Full reports of the 2010 Quick Polls from ASH, SABCS and ASCO are available upon request.
About MDOUTLOOK®
MDOUTLOOK has been developed with a singular focus: improved understanding of complex diseases leading to better patient care. Over 47,000 cancer treating physicians have opted into a network of their peers through the MDOUTLOOK Internet-based system to share information such as preferred treatment regimens for complex diseases and de-identified patient logs, as well as the factors that play a part in their clinical decision-making.
Physician members of MDOUTLOOK benefit by having access to data on how other clinicians in practice treat difficult cases and how they are adapting to changes in the industry, everything from the introduction of new drugs or treatment modalities, to the rising costs of certain treatments. For many physicians, MDOUTLOOK also serves as a patient registry.
MDOUTLOOK is guided a Strategy Council of globally recognized experts: Chandra Belani, MD; Alexander Eggermont, MD, PhD; Keith Flaherty, MD; William Gradishar, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Sagar Lonial, MD; Lauren Pinter-Brown, MD; Giorgio Scagliotti, MD, PhD; Joyce O’Shaughnessy, MD, and Nicholas Thatcher, MD.
MDOUTLOOK delivers life-sciences clients real-time ThoughtLeader and clinician-driven analysis, intelligence and insight into oncology clinical practice (www.thearcasgroup.com/mdoutlook).
About The Arcas Group
The Arcas Group is a strategic life sciences marketing organization with a singular focus: Supporting the commercial success of our clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians. MDOUTLOOK is a key offering that is highly valued by its rapidly expanding base of clients.
For more information, please visit The Arcas Group’s website at www.thearcasgroup.com.
Copy of the release can be found here.
December 21st, 2010
From our entire team, a warm and heartfelt Happy Holidays to our clients and all cancer treaters we have worked with successfully in 2010.
We hope that you have had as successful a year as we have enjoyed. Our team is looking forward to continuing to serve our clients and make a positive impact on cancer care globally.
Have an enjoyable close of 2010 and a wonderful start of 2011.
On behalf of the entire Arcas Team!
Kind regards,
Jan Heybroek, President
PS: I would like to share the following video with you to thank all the people who have visited our website this year, in part through links featured on Google.
December 16th, 2010
We are very pleased to welcome Jan Willem (JW) Gommers, MSc to the leadership of The Arcas Group as Director, Business Development Europe. He joins with more than 15 years of international and local experience in the biopharma industry, established through a variety of roles with increased responsibility.
Earlier in his career, Jan Willem held several management positions with Organon, Amgen and Astrazeneca. Most recently, JW was Business Unit Manager Oncology at GlaxoSmithKline, successfully launching GSK Oncology in The Netherlands. In this role, he directed the market access, sales and product management functions for the Oncology & Hematology portfolio and carried full P&L responsibility. Subsequently, Jan Willem founded Blue Ocean, a Management Consulting company.
“I am excited to have Jan Willem join our team. He is a consummate professional with high energy, great insight and a very significant network in biopharma. JW is a great asset to our company and our clients,” says Jan Heybroek, President of The Arcas Group.
Jan Willem may be reached directly at jwgommers@thearcasgroup.com
October 30th, 2010
Since the summer, key staff of The Arcas Group have been featured in several news articles and interviews. The publications and topics covered provide a good indication of the breadth and depth of our team and insights.
In chronological order, Arcas was featured as follows:
* Oncology Business Review July-August 2010: original article on factors driving use of oncology biomarkers (article, additional research on pg 26, 28)
* Pharmaceutical Executive September 2010: quote in article on Gilead (article, quote is on page 50)
* Pharmaceutical Executive October 2010: in-depth interview on the changing landscape of payers and pharma with a focus on oncology (article). For a downloadable version, you may click here.
We look forward to working with you in addressing your strategic marketing and oncology intelligence challenges. Please contact us here for more information on our Business Optimizer and Outcome Optimizer services or to schedule a demo of our total oncology intelligence platform, MDoutlook.
October 19th, 2010
Atlanta, GA, United States - June 30, 2010
MDOUTLOOK®, the oncology intelligence initiative powered by The Arcas Group, today announced results from its 3rd Annual Quick Poll research launched following this month’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Within one week, 281 cancer treaters from 22 countries responded, making it the first market feedback available post-ASCO. The research yielded the following highlights for these therapeutic segments:
Maintenance Therapy in Hematologic Malignancies:
• Rituximab: Nearly all physicians already use as maintenance therapy in some patients with Follicular Lymphoma. Increase in usage after ASCO driven by physicians using rituximab maintenance in a higher proportion of their patients.
• Lenalidomide: ~75% of physicians are already using some lenalidomide maintenance therapy for Multiple Myeloma, however in a minority of patients. Increase in usage after ASCO driven by more physicians using it in more patients.
• ~3/4 of Physicians found the new information on maintenance therapy in Follicular Lymphoma and Multiple Myeloma of significant value and usefulness to their clinical practice.
Novel Immunotherapies for the Treatment of Cancers:
• Immunotherapy is used in ~15% of oncology treatment decisions, irrespective of line of treatment.
• Ipilumimab: Physician response to new data presented predicts strong market adoption in melanoma and rapid integration into practice (pending FDA approval).
• High-dose aldesleukin (HD-IL-2): Physicians positively view new information presented in renal cell carcinoma (SELECT trial).
• Sipuleucel-T: Physician response predicts moderate market adoption in prostate cancer of this recently FDA-approved product.
Current and Future Use of Oncology Biomarkers:
• Current use of biomarkers to guide diagnosis and treatment decision is heavily weighted towards breast and colorectal cancer (>80% patients).
• Biomarkers are also used in up to 50% of patients with lung cancer, prostate and ovarian cancers; far less in other cancers.
• Oncologists strongly value both FDA indications and inclusion in National Guidelines for their adoption of the biomarker in clinical practice.
• Physician usage of biomarkers is influenced by its patient selection benefits and as well as incremental diagnostic costs.
Developments in Oncology Practice Management:
• Overall survival is considered the most important clinical trial endpoint by oncologists for their clinical decision-making.
• About 1/3 of all respondents attended ASCO, with no country differences. This ratio was consistent in all 2010 MDOUTLOOK Quick Polls and as well as previous years.
Members of the MDOUTLOOK Strategy Council reflected that these results “validate the expected change in physician decision-making” and that “it will be interesting to follow-up on a regular basis to track these changes.”
Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to quickly and in a targeted manner capture the views of validated cancer physicians around the world, and turn this into actionable intelligence.”
The 3rd Annual Quick Polls from ASCO 2010 were developed in collaboration with Arcas’ media partner, Oncology Business Review. More information can be found here.
Full copies of the 3rd Annual MDOUTLOOK Quick Polls from ASCO are available upon request.
About MDOUTLOOK®
MDOUTLOOK has been developed with a singular focus: improved understanding of complex diseases leading to better patient care. Over 45,000 medical oncology professionals have opted into a network of their peers through the MDOUTLOOK Internet-based system to share information such as preferred treatment regimens for complex diseases and de-identified patient logs, as well as the factors that play a part in their clinical decision-making.
Physician members of MDOUTLOOK benefit by having access to data on how other clinicians in practice treat difficult cases and how they are adapting to changes in the industry, everything from the introduction of new drugs or treatment modalities, to the rising costs of certain treatments. For many physicians, MDOUTLOOK also serves as a patient registry.
MDOUTLOOK is guided by a Strategy Council of globally recognized experts: Chandra Belani, MD; Alexander Eggermont, MD, PhD; Keith Flaherty, MD; William Gradishar, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Sagar Lonial, MD; Lauren Pinter-Brown, MD; Giorgio Scagliotti, MD, PhD; Joyce O’Shaughnessy, MD, and Nicholas Thatcher, MD.
MDOUTLOOK delivers life-sciences clients real-time ThoughtLeader and clinician-driven analysis, intelligence and insight into oncology clinical practice (www.thearcasgroup.com/mdoutlook).
About The Arcas Group
The Arcas Group is a strategic life sciences marketing organization with a singular focus: Supporting the commercial success of our clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians. MDOUTLOOK is a key offering that is highly valued by its rapidly expanding base of clients.
For a copy of the original press release, please click here.
July 9th, 2010
Today, Oncology Business Review (OBR) published a great article based on the results from the 3rd Annual MDoutlook Quick Poll following ASCO 2010. You can read the full article on OBR’s website (article). Many thanks to our friends at media partner OBR for developing and releasing this article so quickly after we published the analyzed results.
If you would like to receive a full copy of the MDoutlook Quick Poll analysis or learn more about the value and insight MDoutlook can deliver, please contact us using this form.
June 30th, 2010
We are pleased to report continued growth on a number of fronts!
Our team will welcome two valuable additions in July: Luan Dao, PhD will join the Medical Team as Global Medical Analyst and Jessica Mastrodomenico, MPH will strengthen our Operational Group as Manager, Client Projects. Luan most recently served as a post-doctoral fellow at Emory University with a focus on influenza and HPV. Jessica joins us from the CDC Foundation where she worked while completing her Master of Public Health with a concentration on prevention sciences.
We have also signed up three new clients for MDoutlook, our oncology intelligence platform. The clients specifically focus on prostate cancer, renal cell carcinoma and melanoma. Additionally, Arcas has welcomed new clients to its Outcome Optimizer offering in the area of oncology diagnostics and breast cancer. And our Business Optimizer offering has recently signed up tow consultancy projects focused on physician recruiting and oncology marketing.
Please contact us here for more information and if you are interested in joining a rapidly growing organization, either as client or associate.
June 30th, 2010
Next Posts
Previous Posts
